Iovance Biotherapeutics (IOVA) Stock Forecast & Price Target

Iovance Biotherapeutics has demonstrated a robust 30% sequential growth in 4Q25 product revenue, reaching approximately $87 million, bolstered by a strong demand for Amtagvi and improved gross margins, which increased from 35% to around 50%. The company is effectively expanding its ATC network to enhance patient access, with expectations for further acceleration in 2026, fueled by optimized operational execution and advancements in manufacturing success. Centralizing manufacturing at the iCTC in early 2026 is anticipated to drive additional cost reductions and margin improvements, supporting a favorable outlook as the company prepares for potential regulatory approvals and commercialization of its innovative cancer therapy.

Iovance Biotherapeutics, Inc. has reported higher-than-expected SG&A expenses of $36.4 million, which may indicate increased operational costs that could pressure future profitability. The company's bear case scenario for its lead therapy, lifileucel, suggests a significant risk to commercial success, as the probability of uptake drops to 5% in 2025, coupled with a dependency on regulatory approvals for indications beyond post-checkpoint melanoma that could lead to downward revisions in forecasts. Additionally, the reported decrease in cost of goods sold to 50% from the previous 65% may not sufficiently offset the looming competitive and regulatory risks, contributing to an overall negative outlook for the stock.